PDL BIOPHARMA, INC. - FORM 10-K - EX-32.1 - CERTIFICATION - March 11, 2020

Attached files

file filename
EX-4.8 - DESCRIPTION OF REGISTRANTS SECURITIES - PDL BIOPHARMA, INC.pdli1231201910-kex48.htm
EX-31.2 - CERTIFICATION - PDL BIOPHARMA, INC.pdli1231201910-kex312.htm
EX-31.1 - CERTIFICATION - PDL BIOPHARMA, INC.pdli1231201910-kex311.htm
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - PDL BIOPHARMA, INC.pdli1231201910-kex231.htm
EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - PDL BIOPHARMA, INC.pdli1231201910-kex211.htm
EX-10.76 - WIND DOWN RETENTION PLAN - PDL BIOPHARMA, INC.pdli1231201910-kex1076.htm
EX-10.75 - FORM OF INDUCEMENT RESTRICTED STOCK AGREEMENT - PDL BIOPHARMA, INC.pdli1231201910-kex1075.htm
EX-10.74 - FORM OF NONSTATUTORY INDUCMENT STOCK OPTION AGREEMENT NOTICE SUPPPLEMENT - PDL BIOPHARMA, INC.pdli1231201910-kex1074.htm
EX-10.73 - FORM OF NONSTATUTORY INDUCMENT STOCK OPTION AGREEMENT - PDL BIOPHARMA, INC.pdli1231201910-kex1073.htm
EX-10.72 - FORM OF STOCK OPTION GRANT NOTICE SUPPLEMENT - PDL BIOPHARMA, INC.pdli1231201910-kex1072.htm
EX-10.71 - FORM OF STOCK OPTION AGREEMENT AMENDMENT ACKNOWLEDGEMENT - PDL BIOPHARMA, INC.pdli1231201910-kex1071.htm
EX-10.70 - FORM OF STOCK OPTION AGREEMENT - PDL BIOPHARMA, INC.pdli1231201910-kex1070.htm
EX-10.69 - FORM OF RESTRICTED STOCK AGREEMENT AMENDMENT ACKNOWLEDGEMENT - PDL BIOPHARMA, INC.pdli1231201910-kex1069.htm
EX-10.68 - FORM OF RESTRICTED STOCK AGREEMENT - PDL BIOPHARMA, INC.pdli1231201910-kex1068.htm
EX-10.67 - SEVERANCE PLAN - PDL BIOPHARMA, INC.pdli1231201910-kex1067.htm
EX-10.66 - FIFTH AMENDEMENT TO LEASE AGREEMENT - PDL BIOPHARMA, INC.pdli1231201910-kex1066.htm
10-K - 10-K - PDL BIOPHARMA, INC.pdli1231201910-kdoc.htm


Exhibit 32.1
CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350), Dominique Monnet, President and Chief Executive Officer of PDL BioPharma, Inc. (the “Company”), and Edward A. Imbrogo, Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of their knowledge:

(1) The Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and

(2) The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: March 11, 2020
 
By:
 
 
 
/s/ DOMINIQUE MONNET
 
 
Dominique Monnet
 
 
President and Chief Executive Officer
 
 
(Principal Executive Officer)
 
 
 
 
 
 
 
By:
 
 
 
/s/ EDWARD A. IMBROGNO
 
 
Edward A. Imbrogno
 
 
Vice President and Chief Financial Officer
 
 
(Principal Financial Officer)
_________________________________________
(1)
This certification accompanies the Annual Report on Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of PDL BioPharma, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to PDL BioPharma, Inc. and will be retained by PDL BioPharma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



PDL BIOPHARMA, INC. Reports